Nor)Clozapine Kinetics and Side Effects in Therapy Resistant Schizophrenia and the Optimal Sampling Time for Therapeutic Drug Monitoring

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-12-23

Study Completion Date

2027-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to better understand how clozapine treatment can be tailored as regards minimizing side effects and optimizing efficacy and monitoring. Firstly, how clozapine is broken down into norclozapine in the liver and how both clozapine and norclozapine affect side effects are examined. In order to investigate this metabolization process in the liver inflammation levels in the blood are assessed, which inhibit the conversion of clozapine into norclozapine. In addition, various factors related to physical health are assessed, such as blood sugar, cholesterol, weight, waist circumference, blood pressure and heart rate. The role of hormones is investigated, such as cortisol, a stress hormone that affects metabolism and stress levels. Amino acids are examined, which are building blocks of proteins, and specific parts of DNA that influence clozapine metabolism. In addition, investigation follows whether 12 hours after ingestion is a well-chosen time at which the amount of clozapine is measured in the blood in case of ingestion once a day and twice a day. Finally, specific side effects of clozapine are assessed - with special attention to stool - and the severity of the psychiatric symptoms in patients with therapy resistant schizophrenia spectrum disorders.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rationale:

Therapeutic drug monitoring (TDM) is essential for clozapine and can enhance therapeutic outcomes and minimize side effects. As of yet, research on (nor)clozapine concentrations and their association to metabolic side effects is limited and inconclusive. Unfortunately, not enough is known about individual risk factors for developing metabolic side effects to personalize clozapine treatment. It would be desirable to have another way to predict which clozapine users are at increased risk of developing severe side effects. Current guidelines are based on limited evidence, potentially resulting in inconsistent or suboptimal monitoring and management.

Objective:

The primary objective is to evaluate the correlation between (nor)clozapine kinetics and serum level HbA1c. Secondary objectives include validating an existing population pharmacokinetic model, assessing the validity of the current 12-hour post-intake sampling practice, determining the optimal sampling window for once-daily clozapine TDM and assessing the correlation of other metabolic and multiple laboratory parameters and influence of demographic and clinical parameters on the pharmacokinetics and -dynamics of clozapine and norclozapine.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Side Effects of Clozapine Neutropenia Due to Clozapine General Side Effects of Clozapine Constipation Due to Clozapine Symptoms of Schizophrenia Optimal Blood Sampling Time for Clozapine in Patients Who Receive Clozapine Once and Twice Daily Clozapine and Norclozapine Plasma Level Concentrations

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

cardiovascular side effects neutropenia general side effects of clozapine constipation symptoms of schizophrenia optimal blood sampling time clozapine and norclozapine plasma level concentrations

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adult patients with treatment resistant schizophrenia spectrum disorders receiving clozapine.

Adult patients (age between 18 and 70) with treatment resistant schizophrenia of schizoaffective disorder, treated with oral, once or twice-daily clozapine.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Standard treatment of a stable, oral dose of clozapine for at least one week (at steady state).
* Age between 18-70 years.
* Registered time of intake as well as sampling time and dosage.
* Registered smoking status (yes/no).
* At least two samples in the elimination phase of clozapine with both clozapine and norclozapine measured.
* Measurement of the white cell count at least every three months or more often.
* Routine metabolic screening performed at moment of inclusion.
* Subjects should be able to understand the study information and procedures and give informed consent or when incapacitated subjects are not reliably able to give informed consent their legal representatives should give informed consent under the condition that these subjects are willing to participate.

Exclusion Criteria

* Pregnancy.
* Malignancy or treatment with immunosuppressive medication.
* Samples where cessation, start or dose change of interacting co-medication (such as valproic acid, gemfibrozil, fluvoxamine, omeprazole and cyclic oral contraceptives \[21 on, 7 days off\]) or changes in use of tobacco containing products occurred within seven days prior to blood sampling (21, 28, 34, 35).
* Acute inflammation, infection or samples shortly after intoxication. In case this information is unknown, it may be derived by large unexpected change in levels compared to previous or target levels.
* Not sampled at Starlet (blood collection site) or sampled by dried blood spot
* Unknown status of smoking (including vaping).
* Unknown time of intake of clozapine.
* Unknown time of blood sampling.
* If informed consent is not obtained by the patient or by a legal representative in a mentally incapacitated patient, i.e. a legally incompetent adult.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Paul Bank, PharmD, PhD

Role: PRINCIPAL_INVESTIGATOR

North West Clinics

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Selene Veerman, MD, PhD

Role: CONTACT

Phone: +31623993164

Email: [email protected]

Jan Bogers, MD

Role: CONTACT

Phone: +31613731329

Email: [email protected]

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

COTTONS-v2-22/11/2024

Identifier Type: -

Identifier Source: org_study_id